平均减重25斤、改善“三高”，司美格鲁肽对亚洲人群疗效再获验证！

Core Viewpoint - The article discusses the efficacy of semaglutide in weight loss and metabolic improvement among the Asian population, highlighting significant results from clinical trials that support its use in obesity treatment [2][8]. Group 1: Obesity Definition and Health Risks - The World Health Organization (WHO) defines obesity in the Asian population as BMI≥25 kg/m², which is lower than the global standard of ≥30 kg/m² due to higher body fat percentages and associated health risks in Asians [2][3]. Group 2: Clinical Trial Overview - The STEP 11 trial is a 44-week, randomized, double-blind, placebo-controlled study conducted in South Korea and Thailand, focusing on adults with obesity (BMI≥25 kg/m²) without diabetes [4]. - Participants received either a weekly 2.4 mg subcutaneous injection of semaglutide or a placebo, alongside lifestyle interventions [4]. Group 3: Study Results - A total of 150 participants were randomized, with 101 receiving semaglutide and 49 receiving placebo. The average weight change in the semaglutide group was -16.0% (approximately -12.8 kg), while the placebo group saw a change of -3.1% [5]. - In terms of significant weight loss, 96% of the semaglutide group achieved a weight reduction of ≥5%, compared to 25% in the placebo group [5]. - Waist circumference also decreased significantly in the semaglutide group by -11.9 cm, compared to -3.0 cm in the placebo group [5]. Group 4: Safety and Tolerability - Adverse events were reported by 89% of participants in the semaglutide group and 78% in the placebo group, with gastrointestinal discomfort being the most common side effect [7]. - Serious adverse events occurred in 13% of the semaglutide group and 8% of the placebo group [7]. Group 5: Conclusion and Implications - The study concludes that semaglutide 2.4 mg significantly reduces weight in the Asian obese population and is well-tolerated, suggesting its inclusion in local treatment guidelines [8][9]. - The findings may influence healthcare policies and obesity prevention strategies in Asian countries, emphasizing the importance of population-specific treatment approaches [9].